Ignite Creation Date:
2025-12-24 @ 4:48 PM
Ignite Modification Date:
2025-12-28 @ 6:00 AM
Study NCT ID:
NCT06360250
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-11
First Post:
2024-04-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation
Sponsor:
Changchun BCHT Biotechnology Co.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-10
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-10-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-10-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-07
First Submit QC Date:
None
Study First Post Date:
2024-04-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-07
Last Update Post Date:
2024-04-11
Last Update Post Date Type:
ACTUAL